997P Phase I study of brigatinib plus panitumumab in patients with advanced EGFR-mutated non-small cell lung cancer resistant to osimertinib (BEBOP): Early termination due to severe early onset pneumonitis by brigatinib

Abstract

Osimertinib is a standard of care for advanced EGFR-mutated non-small cell lung cancer (EGFR+NSCLC), however acquired resistance inevitably develop in 1-2 year. No effective targeted therapy has been established for EGFR+NSCLC after osimertinib. The EGFR C797S (CS) mutation is one of the most common resistant mechanisms to osimertinib. Brigatinib is shown to overcome CS-mediated osimertinib resistance in combination with anti-EGFR antibody in preclinical models.